πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 81 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10233170

2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

Rigel Pharmaceuticals, Inc. Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233244

Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. Β· Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10208081

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. Β· Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10167334

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

The Regents of the University of California Β· Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10118961

Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV

CytomX Therapeutics, Inc. Β· Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072122

Carbonate polymer containing a functional group of disulfide five-membered ring in the sid

BRIGHTGENE BIO-MEDICAL TECHNOLOGY (SUZHOU) CO., LTD. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884868

TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868954

Reduction of TGFΞ² signaling in myeloid cells in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9796728

Cyclic carbonate monomer containing double-sulfur five-membered ring functional group, and

BrightGene Bio-Medical Technology Co., Ltd. Β· Granted Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9694071

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. Β· Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9562237

Reduction of TGF beta signaling in myeloid cells in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9115371

Reduction of TGF beta signaling in myeloid cells in the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9078918

Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)

Northwestern University Β· Granted Tue Jul 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8969296

TGFP-CAP peptide and its uses

CAREGEN CO., LTD. Β· Granted Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946172

Method for reducing scarring during wound healing using antisense compounds directed to CT

Northwestern University Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8765797

TG2 inhibitors and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8754046

MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8530167

Diagnostic and therapeutic uses of GNPTAB, GNPTG, and NAGPA in stuttering

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 10 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8507463

Nucleotide analogue prodrug and the preparation thereof

BrightGene Bio-Medical Technology Co., Ltd. Β· Granted Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8133861

Systemic purine administration: modulating axonal outgrowth of central nervous system neur

Alseres Pharmaceuticals, Inc. Β· Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7846908

RNAi modulation of TGF-beta and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7795267

Bicyclic piperazine compound having TGR23 antagonistic activity

Takeda Pharmaceutical Company Limited Β· Granted Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7795389

Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combina

The Board of Regents of the University of Texas System Β· Granted Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7553484

Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) mol

The Regents of the University of California Β· Granted Tue Jun 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 25 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted